Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
12.65 EUR | +0.80% |
|
+7.33% | -25.31% |
Jun. 04 | ORPEA : Integrating the detailed FY23 figures | ![]() |
Jun. 04 | Emeis: sale of real estate assets in Ireland | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.31% | 2.15B | B- | ||
+19.22% | 1.7B | - | C+ | |
+25.95% | 1.41B | - | B | |
-25.26% | 1.35B | - | ||
+24.98% | 765M | - | B | |
-17.27% | 404M | - | B- | |
+226.08% | 414M | - | D+ | |
-18.54% | 285M | - | - | |
+21.14% | 165M | - | B | |
+32.10% | 85.34M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EMEIS Stock
- Ratings EMEIS